140 related articles for article (PubMed ID: 38184691)
1. Management of non-metastatic anal cancer in the elderly: ancillary study of the French multicenter prospective cohort FFCD-ANABASE.
Gouriou C; Lemanski C; Pommier P; Le Malicot K; Saint A; Rivin Del Campo E; Evin C; Quero L; Regnault P; Baba-Hamed N; Ronchin P; Crehange G; Tougeron D; Menager-Tabourel E; Diaz O; Hummelsberger M; de la Rocherfordiere A; Drouet F; Vendrely V; Lièvre A
Br J Cancer; 2024 Mar; 130(5):769-776. PubMed ID: 38184691
[TBL] [Abstract][Full Text] [Related]
2. Treatment, outcome, and prognostic factors in non-metastatic anal cancer: The French nationwide cohort study FFCD-ANABASE.
Vendrely V; Lemanski C; Pommier P; LE Malicot K; Saint A; Rivin Del Campo E; Regnault P; Baba-Hamed N; Ronchin P; Crehange G; Tougeron D; Menager-Tabourel E; Diaz O; Hummelsberger M; Minsat M; Drouet F; Larrouy A; Peiffert D; Lievre A; Zasadny X; Hautefeuille V; Mornex F; Lepage C; Quero L;
Radiother Oncol; 2023 Jun; 183():109542. PubMed ID: 36813175
[TBL] [Abstract][Full Text] [Related]
3. What is the optimal treatment for T1N0 anal squamous cell carcinoma? Analysis of current practices in the prospective French FFCD ANABASE cohort.
Bacci M; Quero L; Barbier E; Parrot L; Juguet F; Pommier P; Bazire L; Etienney I; Baba-Hamed N; Spindler L; François E; Ronchin P; Campo ERD; Lemanski C; Lièvre A; Siproudhis L; Abramowitz L; Lepage C; Vendrely V
Dig Liver Dis; 2021 Jun; 53(6):776-784. PubMed ID: 33867291
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
Kim S; Jary M; André T; Vendrely V; Buecher B; François E; Bidard FC; Dumont S; Samalin E; Peiffert D; Pernot S; Baba-Hamed N; El Hajbi F; Bouché O; Desrame J; Parzy A; Zoubir M; Louvet C; Bachet JB; Nguyen T; Abdelghani MB; Smith D; De La Fouchardière C; Aparicio T; Bennouna J; Gornet JM; Jacquin M; Bonnetain F; Borg C
BMC Cancer; 2017 Aug; 17(1):574. PubMed ID: 28841909
[TBL] [Abstract][Full Text] [Related]
5. Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: Results of the FFCD 0904 phase II trial.
Vendrely V; Ronchin P; Minsat M; Le Malicot K; Lemanski C; Mirabel X; Etienne PL; Lièvre A; Darut-Jouve A; de la Fouchardière C; Giraud N; Breysacher G; Argo-Leignel D; Thimonnier E; Magné N; Abdelghani MB; Lepage C; Aparicio T;
Radiother Oncol; 2023 Sep; 186():109742. PubMed ID: 37315583
[TBL] [Abstract][Full Text] [Related]
6. French multicentre clinical evaluation of helical TomoTherapy for anal cancer in a cohort of 64 consecutive patients.
Vendrely V; Henriques de Figueiredo B; Rio E; Benech J; Belhomme S; Lisbona A; Frison E; Doussau A; Nomikossoff N; Mahé MA; Kantor G; Maire JP
Radiat Oncol; 2015 Aug; 10():170. PubMed ID: 26268888
[TBL] [Abstract][Full Text] [Related]
7. A Phase II Study of Capecitabine/Oxaliplatin With Concurrent Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Anal Canal.
Eng C; Jácome AA; Das P; Chang GJ; Rodriguez-Bigas M; Skibber JM; Wolff RA; Qiao W; Xing Y; Sethi S; Ohinata A; Crane CH
Clin Colorectal Cancer; 2019 Dec; 18(4):301-306. PubMed ID: 31350201
[TBL] [Abstract][Full Text] [Related]
8. Chemoradiotherapy for squamous cell carcinoma of the anal canal: Comparison of one versus two cycles mitomycin-C.
White EC; Goldman K; Aleshin A; Lien WW; Rao AR
Radiother Oncol; 2015 Nov; 117(2):240-5. PubMed ID: 26347494
[TBL] [Abstract][Full Text] [Related]
9. Locally Advanced (T3-T4 or N+) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy.
Franco P; Arcadipane F; Ragona R; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
Anticancer Res; 2016 Apr; 36(4):2027-32. PubMed ID: 27069197
[TBL] [Abstract][Full Text] [Related]
10. Impact of tobacco smoking on the patient's outcome after (chemo)radiotherapy for anal cancer.
Lerman J; Hennequin C; Etienney I; Abramowitz L; Goujon G; Gornet JM; Guillerm S; Aparicio T; Valverde A; Cattan P; Quéro L
Eur J Cancer; 2020 Dec; 141():143-151. PubMed ID: 33137590
[TBL] [Abstract][Full Text] [Related]
11. Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Kim S; Buecher B; André T; Jary M; Bidard FC; Ghiringhelli F; François É; Taieb J; Smith D; de la Fouchardière C; Desramé J; Samalin E; Parzy A; Baba-Hamed N; Bouché O; Tougeron D; Dahan L; El Hajbi F; Jacquin M; Rebucci-Peixoto M; Spehner L; Vendrely V; Vernerey D; Borg C
BMC Cancer; 2020 Apr; 20(1):352. PubMed ID: 32334548
[TBL] [Abstract][Full Text] [Related]
12. Review of anal cancer patients at the Ottawa hospital.
Abunassar M; Reinders J; Jonker DJ; Asmis T
Eur J Surg Oncol; 2015 May; 41(5):653-8. PubMed ID: 25776438
[TBL] [Abstract][Full Text] [Related]
13. Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort.
Bentzen AG; Guren MG; Wanderås EH; Frykholm G; Tveit KM; Wilsgaard T; Dahl O; Balteskard L
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):e173-80. PubMed ID: 22436791
[TBL] [Abstract][Full Text] [Related]
14. Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial.
Glynne-Jones R; Kadalayil L; Meadows HM; Cunningham D; Samuel L; Geh JI; Lowdell C; James R; Beare S; Begum R; Ledermann JA; Sebag-Montefiore D;
Ann Oncol; 2014 Aug; 25(8):1616-22. PubMed ID: 24827136
[TBL] [Abstract][Full Text] [Related]
15. Comparative Survival of Patients With Anal Adenocarcinoma, Squamous Cell Carcinoma of the Anus, and Rectal Adenocarcinoma.
Franklin RA; Giri S; Valasareddy P; Lands LT; Martin MG
Clin Colorectal Cancer; 2016 Mar; 15(1):47-53. PubMed ID: 26362848
[TBL] [Abstract][Full Text] [Related]
16. Salvage Abdominoperineal Resection for Anal Squamous Cell Carcinoma: Use, Risk Factors, and Outcomes in a Canadian Population.
Patel SV; Ko G; Raphael MJ; Booth CM; Brogly SB; Kalyvas M; Li W; Hanna T
Dis Colon Rectum; 2020 Jun; 63(6):748-757. PubMed ID: 32384405
[TBL] [Abstract][Full Text] [Related]
17. Impact of dose escalation on colostomy-free survival and treatment outcome in squamous cell anal carcinoma.
Untiedt S; Rolf D; Scobioala S; Wolters H; Elsayad K; Oertel M; Kittel C; Pascher A; Rijcken E; Ullerich H; Glasbrenner B; Eich HT
Strahlenther Onkol; 2023 Aug; 199(8):749-760. PubMed ID: 36862155
[TBL] [Abstract][Full Text] [Related]
18. Concomitant chemoradiotherapy with Cisplatin plus 5-Fluorouracil for anal squamous cell carcinoma.
El-Hadaad HA; Wahba HA; Roshdy S
J Gastrointest Cancer; 2015 Jun; 46(2):156-60. PubMed ID: 25810165
[TBL] [Abstract][Full Text] [Related]
19. Intensity-modulated radiotherapy and cisplatin-based chemotherapy for anal cancer: long-term outcomes at a single institution.
Gerardi MA; Zerella MA; Bergamaschi L; Ferrari A; Arculeo S; Bagnardi V; Frassoni S; Petz W; Fodor C; Emiro F; Cattani F; Leonardi MC; Zampino MG; Jereczek-Fossa BA
Int J Colorectal Dis; 2023 May; 38(1):123. PubMed ID: 37162567
[TBL] [Abstract][Full Text] [Related]
20. Primary surgery with or without postoperative radiotherapy in early stage squamous cell carcinoma in the anal canal and anal margin.
Leon O; Hagberg O; Johnsson A
Acta Oncol; 2018 Sep; 57(9):1209-1215. PubMed ID: 29490558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
